| Dr Simha E Ravven, MD | |
|
300 Flynn Ave, Burlington, VT 05401-5301 | |
| (802) 488-6000 | |
| (802) 488-6919 |
| Full Name | Dr Simha E Ravven |
|---|---|
| Gender | Female |
| Speciality | Psychiatry |
| Experience | 15 Years |
| Location | 300 Flynn Ave, Burlington, Vermont |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1629210281 | NPI | - | NPPES |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Howardcenter, Inc. | 3072403831 | 28 |
News Archive
Researchers at the University of Arizona have invented a device that for the first time allows neurosurgeons, who use microscopes extensively while operating, to see blood flowing inside vessels and more clearly distinguish cancerous from healthy tissue under the microscope.
Historically, randomized controlled trials have served as the state-of-the-art method for determining the efficacy and safety of new, innovative treatment regimens for patients with cancer and other diseases.
Regeneron Pharmaceuticals, Inc. and Sanofi announced today that a Phase 3 study of sarilumab, an investigational, fully human IL-6 receptor antibody, met its co-primary efficacy endpoints of a greater improvement in signs and symptoms of rheumatoid arthritis (RA) at 24 weeks and physical function at 12 weeks, compared to placebo.
Plug the terms "alternative" and "cancer" into Google and the Internet search engine returns a list of 3.27 million - yes, million - sites with information both credible and questionable about nontraditional treatments for cancer. What's a cancer patient to make of such a vast array of options?
› Verified 2 days ago
| Entity Name | Howardcenter, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1639267404 PECOS PAC ID: 3072403831 Enrollment ID: O20041029000184 |
News Archive
Researchers at the University of Arizona have invented a device that for the first time allows neurosurgeons, who use microscopes extensively while operating, to see blood flowing inside vessels and more clearly distinguish cancerous from healthy tissue under the microscope.
Historically, randomized controlled trials have served as the state-of-the-art method for determining the efficacy and safety of new, innovative treatment regimens for patients with cancer and other diseases.
Regeneron Pharmaceuticals, Inc. and Sanofi announced today that a Phase 3 study of sarilumab, an investigational, fully human IL-6 receptor antibody, met its co-primary efficacy endpoints of a greater improvement in signs and symptoms of rheumatoid arthritis (RA) at 24 weeks and physical function at 12 weeks, compared to placebo.
Plug the terms "alternative" and "cancer" into Google and the Internet search engine returns a list of 3.27 million - yes, million - sites with information both credible and questionable about nontraditional treatments for cancer. What's a cancer patient to make of such a vast array of options?
› Verified 2 days ago
| Entity Name | Brattleboro Retreat |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1730185232 PECOS PAC ID: 7012828908 Enrollment ID: O20041123000627 |
News Archive
Researchers at the University of Arizona have invented a device that for the first time allows neurosurgeons, who use microscopes extensively while operating, to see blood flowing inside vessels and more clearly distinguish cancerous from healthy tissue under the microscope.
Historically, randomized controlled trials have served as the state-of-the-art method for determining the efficacy and safety of new, innovative treatment regimens for patients with cancer and other diseases.
Regeneron Pharmaceuticals, Inc. and Sanofi announced today that a Phase 3 study of sarilumab, an investigational, fully human IL-6 receptor antibody, met its co-primary efficacy endpoints of a greater improvement in signs and symptoms of rheumatoid arthritis (RA) at 24 weeks and physical function at 12 weeks, compared to placebo.
Plug the terms "alternative" and "cancer" into Google and the Internet search engine returns a list of 3.27 million - yes, million - sites with information both credible and questionable about nontraditional treatments for cancer. What's a cancer patient to make of such a vast array of options?
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Simha E Ravven, MD 208 Flynn Ave Ste 3j, Burlington, VT 05401-5420 Ph: (802) 488-6920 | Dr Simha E Ravven, MD 300 Flynn Ave, Burlington, VT 05401-5301 Ph: (802) 488-6000 |
News Archive
Researchers at the University of Arizona have invented a device that for the first time allows neurosurgeons, who use microscopes extensively while operating, to see blood flowing inside vessels and more clearly distinguish cancerous from healthy tissue under the microscope.
Historically, randomized controlled trials have served as the state-of-the-art method for determining the efficacy and safety of new, innovative treatment regimens for patients with cancer and other diseases.
Regeneron Pharmaceuticals, Inc. and Sanofi announced today that a Phase 3 study of sarilumab, an investigational, fully human IL-6 receptor antibody, met its co-primary efficacy endpoints of a greater improvement in signs and symptoms of rheumatoid arthritis (RA) at 24 weeks and physical function at 12 weeks, compared to placebo.
Plug the terms "alternative" and "cancer" into Google and the Internet search engine returns a list of 3.27 million - yes, million - sites with information both credible and questionable about nontraditional treatments for cancer. What's a cancer patient to make of such a vast array of options?
› Verified 2 days ago
Rebecca Burch, M.D. Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 1 S Prospect St, Burlington, VT 05401 Phone: 802-847-4589 | |
Dr. Dhruv Shah, DO Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 111 Colchester Ave, Burlington, VT 05401 Phone: 802-847-0000 | |
Judith L Lewis, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 111 Colchester Avenue, Fletcher Allen Health Care, Burlington, VT 05401 Phone: 804-847-2791 Fax: 802-847-2733 | |
Ms. Laura Lynn Sponseller, M.D. Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 111 Colchester Ave, Fahc Department Of Psychiatry, Patrick 4, Burlington, VT 05401 Phone: 802-829-9645 | |
Lisa Deuel Baker, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 1 S Prospect St, Burlington, VT 05401 Phone: 802-847-4589 | |
Dr. Robert A Pierattini, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 1 S Prospect St, Burlington, VT 05401 Phone: 802-847-4560 Fax: 802-847-8747 | |
Dr. Edward George Boyer Iv, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 111 Colchester Ave, Burlington, VT 05401 Phone: 802-847-4589 |